Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 24, 2015 4:52 PM ET


Company Overview of Genentech, Inc.

Company Overview

Genentech, Inc., a biotechnology company, engages in the research, development, manufacture, and marketing of biotechnology products for treating patients with serious or life-threatening diseases in the United States. It offers molecular entities and medicines in the areas of oncology, immunology, neuroscience, metabolism, and infectious diseases. The company also offers hematology medicines that include antibody-drug conjugates, small molecule antagonists, and small molecule BCL-2 inhibitors. Genentech, Inc. has a strategic alliance with Array biopharma. The company was founded in 1976 and is headquartered in South San Francisco, California. Genentech, Inc. operates as a subsidiary of Roch...

1 DNA Way Mailstop 258A

South San Francisco, CA 94080-4990

United States

Founded in 1976

11,186 Employees





Key Executives for Genentech, Inc.

Chief Executive Officer, Head of North American Commercial Operations and Director
Age: 53
Co-Founder and Member of Scientific Resource Board
Age: 77
Senior Vice President and General Counsel
Chief Compliance Officer, Head of Legal Affairs for North America, Senior Vice President and Secretary
Vice President of Human Resources and Regional Human Resources Head of North America
Compensation as of Fiscal Year 2014.

Genentech, Inc. Key Developments

Genentech’s Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung Cancer

Genentech announced positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib, its oral investigational anaplastic lymphoma kinase (ALK) inhibitor, shrank tumors (overall response rate; ORR: 50.0% and 47.8%, respectively) in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed following treatment with crizotinib. In addition, alectinib was shown to shrink tumors in people whose cancer had spread to the central nervous system (CNS) (CNS ORR: 57.1% and 68.8%, respectively). People whose tumors shrank in response to alectinib continued to respond for a median of 11.2 and 7.5 months, respectively (duration of response; DOR). Alectinib demonstrated a safety profile consistent with that observed in previous studies. The most common adverse events (Grade 3 or higher occurring in at least 2% of people) were an increase in muscle enzymes (increased blood levels of creatine phosphokinase), increased liver enzymes and shortness of breath (dyspnea).

WaferGen Bio-systems, Inc. Announces Research Collaboration with Genentech Initiating its Early Access Program for Single Cell Genomics Technology

WaferGen Bio-systems, Inc. announced that the Company has signed a research collaboration with Genentech to evaluate and apply WaferGen's SmartChipTM platform in single cell sequencing. The joint work is aimed at validating the utility of the SmartChipTM technology for isolating single cells from various tissues and preparing libraries for Next-Generation Sequencing (NGS). Â Genentech represents WaferGen's initial partner in WaferGen's single cell genomics technology-focused Early Access Program. WaferGen successfully completed separate proof-of-concept studies related to isolating single cells with the SmartChipTM earlier this year with both the Broad Institute and BGI. At the throughput level scalable to several thousand cells per sample, the cell's genetic composition was successfully analyzed via the NGS method, thereby demonstrating increased discovery potential in a single workflow. WaferGen continues to believe that the SmartChipTM technology will be able to yield a 50-fold increase in the production of single cells per chip versus current technologies at a fraction of the per cell cost.

Genentech, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 02:30 PM

Genentech, Inc. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-08-2015 02:30 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Jacqueline Grant, Manager Business Development Neuroscience.

Similar Private Companies By Industry

Company Name Region
Immunotherapy Worldwide United States
Pregentis Inc. United States
Revimmune, Inc United States
ImmuRx, Inc. United States
Aventis Cambridge Genomics Center LLC United States

Recent Private Companies Transactions

July 1, 2014
Seragon Pharmaceuticals Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genentech, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at